Drugs / Glutamic Acid Decarboxylase
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02002130 Comparator | Jan 2015 → Oct 2021 | type 1 diabetes mellitus | University of Alabama at Birmingham | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glutamic Acid Decarboxylase | “Patients will receive a primary (at baseline)injection of recombinant human GAD(Glutamic Acid Decarboxylase) in a standard vaccine formulation with alum, and a booster...” NCT02002130 ↗ |
| Known as | GAD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02002130 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human GAD(Glutamic Acid Decarboxylase)” NCT02002130 ↗ |
| Route | Other | “booster injection of the same at 1 month after baseline” NCT02002130 ↗ |